Studienregister der Deutschen Gesellschaft für Urologie e.V.
- Benigne Prostatahyperplasie (Beschreibung)
- Erektile Dysfunktion
- Harnblasenkarzinom (Beschreibung)
- Harninkontinenz
- Hodentumor (Beschreibung)
- Nierenzellkarzinom (Beschreibung)
- Prostatakarzinom (Beschreibung)
- ALSYMPCA: A double-blind, randomised, multiple dose, phase III, multicentre study of AlpharadinTM in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases
- AP 52/08 - Enthuse M0: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD 4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
- AP 55/09 - SEAL: Prospective randomized trial comparing an extensive with a limited pelvic lymphadenectomy in the context of radical prostatectomy
- AP 59/10 - OGX-011-11: A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer
- COPCa: Coping with Prostate Cancer
- g-Rampp: Multicentric, Prospective, Randomized Controlled Trial Comparing Radical Prostatectomy Plus Neoadjuvant Hormones With Androgen Deprivation Therapy Alone in the Management of Men With Pauci-metastatic Prostate Cancer
- HAROW-Studie: Therapy situation of men with newly diagnosed locally confined prostate cancer in Germany - a prospective evaluation study
- MATuRITY: Management of Advanced prostate cancer in senior adults: a prospective international registry
- PROTEUS: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
- QoLiTax:
- @-Registry-Studie: not available
- SCOPE: Non-interventional study to evaluate the influence of the sequence in which Cabazitaxel is applied on the outcome of patients with metastatic castration-resistant prostate cancer treated with Cabazitaxel (SCOPE)
- SEAL2 (AP77/13 der AUO): n.a. - german study
- Soma-47-Studie:
- TRITON 2_CO-338-052: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
- TRITON 3_CO-338-063: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
- TULSA-PRO: Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
- Überaktive Blase (Beschreibung)
- Urothelkarzinom (Beschreibung)